Preliminary, Real-world, Multicenter Experience With Omadacycline for Mycobacterium abscessus Infections

Preliminary, Real-world, Multicenter Experience With Omadacycline for Mycobacterium abscessus Infections

Abstract Twelve patients were treated with omadacycline (OMC) as part of a multidrug regimen for Mycobacterium abscessus. The majority of infections were of pulmonary origin (7/12; 58.3%). The median (interquartile range) duration of OMC was 6.2 (4.2–11.0) months. Clinical success occurred in 9/12 (...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Open Forum Infectious Diseases 2021-02, Vol.8 (2), p.ofab002-ofab002
Hauptverfasser: Morrisette, Taylor, Alosaimy, Sara, Philley, Julie V, Wadle, Carly, Howard, Catessa, Webb, Andrew J, Veve, Michael P, Barger, Melissa L, Bouchard, Jeannette, Gore, Tristan W, Lagnf, Abdalhamid M, Ansari, Iman, Mejia-Chew, Carlos, Cohen, Keira A, Rybak, Michael J
Format: Artikel
Sprache:eng
Schlagworte:
Brief Reports
Drug resistance
Health aspects
Imipenem
Medical care, Cost of
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Twelve patients were treated with omadacycline (OMC) as part of a multidrug regimen for Mycobacterium abscessus. The majority of infections were of pulmonary origin (7/12; 58.3%). The median (interquartile range) duration of OMC was 6.2 (4.2–11.0) months. Clinical success occurred in 9/12 (75.0%) patients. Three patients experienced a possible adverse effect while on therapy.
ISSN:2328-8957
2328-8957
DOI:10.1093/ofid/ofab002